Daily Med News

FDA widens Ryaltris approval, now for patients 6 years and older

The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged 6 years and older, according to a press release.The fixed-dose combination Ryaltris (Glenmark Pharmaceuticals) nasal spray was approved for adults and children aged 12 years and older in 2022. It…

Source: Healio News

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]